NASDAQ:RDUS Radius Health Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Radius Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.04 -0.51 (-4.06 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$11.78Now: $12.04▼$12.7150-Day Range$11.47MA: $12.04▼$13.1552-Week Range$10.32Now: $12.04▼$29.89Volume969,756 shsAverage Volume611,332 shsMarket Capitalization$559.52 millionP/E RatioN/ADividend YieldN/ABeta1 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingRadius Health has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.25, Radius Health has a forecasted upside of 84.8% from its current price of $12.04.Amount of Analyst CoverageRadius Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesRadius Health has received 502 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRadius Health has received 404 “underperform” votes. (Add your “underperform” vote.)Community SentimentRadius Health has received 55.41% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote “Outperform” if you believe RDUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRadius Health does not currently pay a dividend.Dividend GrowthRadius Health does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Radius Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,923,249.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.92% of the stock of Radius Health is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Radius Health are expected to grow in the coming year, from ($2.50) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Radius Health is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Radius Health is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDUS Previous Symbol CUSIPN/A CIK1428522 Webwww.radiuspharm.com Phone617-551-4000Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$173.32 million Price / Sales3.23 Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-13.09Profitability EPS (Most Recent Fiscal Year)($2.89) Net Income$-132,990,000.00 Net Margins-67.99% Return on EquityN/A Return on Assets-66.22%Miscellaneous Employees398 Outstanding Shares46,472,000Market Cap$559.52 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $12.04 -0.51 (-4.06 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RDUS News and Ratings via Email Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter. Radius Health (NASDAQ:RDUS) Frequently Asked Questions How has Radius Health's stock price been impacted by Coronavirus (COVID-19)? Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS stock has decreased by 25.0% and is now trading at $12.04. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Radius Health? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Radius Health. When is Radius Health's next earnings date? Radius Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Radius Health. How were Radius Health's earnings last quarter? Radius Health Inc (NASDAQ:RDUS) issued its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.82) by $0.13. The biopharmaceutical company had revenue of $50.11 million for the quarter, compared to the consensus estimate of $48.43 million. View Radius Health's earnings history. What price target have analysts set for RDUS? 8 analysts have issued 12-month price targets for Radius Health's shares. Their forecasts range from $14.00 to $28.00. On average, they expect Radius Health's share price to reach $22.25 in the next year. This suggests a possible upside of 84.8% from the stock's current price. View analysts' price targets for Radius Health. Are investors shorting Radius Health? Radius Health saw a increase in short interest in August. As of August 14th, there was short interest totaling 7,280,000 shares, an increase of 8.5% from the July 30th total of 6,710,000 shares. Based on an average trading volume of 612,200 shares, the days-to-cover ratio is presently 11.9 days. View Radius Health's Short Interest. Who are some of Radius Health's key competitors? Some companies that are related to Radius Health include Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), I-Mab (IMAB), Corcept Therapeutics (CORT), Zymeworks (ZYME), Humanigen (HGEN), Eidos Therapeutics (EIDX), CytoDyn (CYDY), Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH), Seres Therapeutics (MCRB), Madrigal Pharmaceuticals (MDGL) and Uniqure (QURE). View all competitors. What other stocks do shareholders of Radius Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), EXACT Sciences (EXAS), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Micron Technology (MU) and Netflix (NFLX). Who are Radius Health's key executives? Radius Health's management team includes the following people: Mr. Jesper Høiland, Pres, CEO & Director (Age 59)Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)Mr. Brian Nicholas Harvey, Advisor (Age 58)Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board What is Radius Health's stock symbol? Radius Health trades on the NASDAQ under the ticker symbol "RDUS." Who are Radius Health's major shareholders? Radius Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bellevue Group AG (15.08%), Vanguard Group Inc. (9.55%), Emerald Advisers LLC (1.93%), Jacobs Levy Equity Management Inc. (1.43%), Two Sigma Advisers LP (1.18%) and Hudson Bay Capital Management LP (1.15%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere. View institutional ownership trends for Radius Health. Which institutional investors are selling Radius Health stock? RDUS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, FMR LLC, FMR LLC, State of Wisconsin Investment Board, Amia Capital LLP, Emerald Advisers LLC, and TD Asset Management Inc.. View insider buying and selling activity for Radius Health. Which institutional investors are buying Radius Health stock? RDUS stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Vanguard Group Inc., Hudson Bay Capital Management LP, Marshall Wace LLP, MERIAN GLOBAL INVESTORS UK Ltd, Charles Schwab Investment Management Inc., Two Sigma Advisers LP, and Marshall Wace North America L.P.. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech. View insider buying and selling activity for Radius Health. How do I buy shares of Radius Health? Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Radius Health's stock price today? One share of RDUS stock can currently be purchased for approximately $12.04. How big of a company is Radius Health? Radius Health has a market capitalization of $559.52 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe. What is Radius Health's official website? The official website for Radius Health is www.radiuspharm.com. How can I contact Radius Health? Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
